| Formulary Chapter 13: Skin - Full Chapter
|
| 13.05.02 |
Preparations for psoriasis |
|
|
|
|
| 13.05.02 |
Topical preparations for psoriasis |
|
|
Coal Tar Solution 12%, Salicylic Acid 2%, precipitated Sulfur 4% (Sebco®)
|
First Choice
|
40g, 100g
|
|
|
Coal tar lotion (Exorex®)
|
Formulary
|
|
|
|
Shampoos (T/Gel®)
|
Formulary
|
125ml, 250ml
|
|
|
Coal Tar 2% with Salicylic Acid 2%
|
Formulary
|
ointment
|
|
|
Dithranol (Dithrocream®)
|
Formulary
|
Cream - 0.1%, 0.25%, 0.5%, 1.0%, 2.0%
1st line Dithranol preperations
|
|
|
Calcipotriol 50micrograms/g with Betamethasone 0.05% (Dovobet®)
|
Formulary
|
Gel, ointment
1st line other topical preperations
|
|
|
Calcipotriol 50microgram/g, (0.005%) (Dovonex)
|
Formulary
|
Ointment, scalp application
|
|
|
Calcipotriol and betamethasone dipropionate Enstilar Cutaneous Foam
|
Formulary
|
60g foam
|
|
|
Dithranol with Salicylic Acid
(Indication: Chronic plaque psoriasis predominantly used as short contact treatment for outpatients coming in for daily treatments)
|
 Unlicensed
|
Dithranol 1% and salicyclic acid 2% in emulsifying ointment 100g
Dithranol 2% and salicyclic acid 2% in emulsifying ointment 100g
Dithranol 4% and salicyclic acid 2% in emulsifying ointment 100g
Dithranol 8% and salicyclic acid 2% in emulsifying ointment 100g
Dithranol 16% and salicyclic acid 2% in emulsifying ointment 100g
|
|
|
Coal tar strong solution 1%, 2.5% & 5% in emulsifying Ointment
|
Unlicensed
|
|
 Special from secondary care. For more information see: Specials recommended by the British Association of dermatologists for Skin Disease.
|
Salicylic acid: in emulsifying ointment Salicyclic acid 2% in aqueous cream 100g (Salicylic acid)
(2%, 5%, 10% and 20%)
|
Unlicensed
|
|
Special from secondary care. For more information see: Specials recommended by the British Association of dermatologists for Skin Disease.
|
Tar Pomade Pomade containing 6% coal tar solution and salicylic acid 2% in an emulsifying ointment base (Tar Pomade)
|
Unlicensed
|
|
Special from secondary care. For more information see: Specials recommended by the British Association of dermatologists for Skin Disease.
|
Zinc & Coal Tar (White’s Tar Paste) Paste containing zinc oxide 6%, coal tar 6%, emulsifying wax 5%, starch 38% and yellow soft paraffin 45%. (Zinc & Coal Tar (White’s Tar Paste) )
|
Unlicensed
|
|
|
|
Zinc and Salicylic Acid Paste BP (Half Strength Lassar’s Paste)
|
Unlicensed
|
|
Special from secondary care. For more information see: Specials recommended by the British Association of dermatologists for Skin Disease.
|
Dithranol in Full Strength Lassar’s Paste
|
Unlicensed
|
0.1%, 0.2%, 0.4%, 0.6%, 0.8%, 1%, 2%, 4%, 6%, 8%
|
Special from secondary care. For more information see: Specials recommended by the British Association of dermatologists for Skin Disease.
|
| 13.05.02 |
Oral retinoids for psoriasis |
|
|
| .... |
| Non Formulary Items |
Alphosyl HC® cream
|
Non Formulary
|
|
|
|
Calcipotriol
|
Non Formulary
|
|
|
|
Calcitriol 3micrograms/g (Silkis®)
|
Non Formulary
|
|
|
|
Coal Tar 10% (Carbo-Dome®)
|
Non Formulary
|
|
|
|
Coal Tar in Lassars Paste
|
Non Formulary
|
|
|
|
Coal Tar in Unguentum M
|
Non Formulary
|
|
|
|
Coal Tar Solution 2.5%, Arachis (peanut) Oil extract of Coal Tar 7.5%, Tar 7.5%, Cade Oil 7.5%, Liqiud Paraffin 35% (Polytar Emollient®)
|
Non Formulary
|
|
|
|
Dithranol (Micanol®)
|
Non Formulary
|
|
|
|
Dithranol (Psorin®)
|
Non Formulary
|
|
|
|
Dithranol Ointment BP
|
Non Formulary
|
|
|
|
Dithranol Paste BP
|
Non Formulary
|
|
|
|
Salicylic Acid 3% w/w, Sulphur 3% w/w in Aqueous Cream
|
Non Formulary
|
|
|
|
Salicylic Acid in White Soft Paraffin
|
Non Formulary
|
|
|
|
Tacalcitol (Curatoderm®)
|
Non Formulary
|
|
|
|
Tars
|
Non Formulary
|
|
|
|
Tars
|
Non Formulary
|
|
|
|
Tars
|
Non Formulary
|
|
|
|
Tars (Clinitar®)
|
Non Formulary
|
|
|
|
Tars (Cocois®)
|
Non Formulary
|
|
|
|
Tars (Psoriderm®)
|
Non Formulary
|
|
|
|
Tars (Zinc and Coal Tar Paste®)
|
Non Formulary
|
|
|
|
Tars - bath preparations
|
Non Formulary
|
|
|
|
Tars - bath preparations (Pinetarsol®)
|
Non Formulary
|
|
|
|
Tars - bath preparations (Psoriderm®)
|
Non Formulary
|
|
|
|
Tazarotene 0.05% (Zorac®)
|
Non Formulary
|
|
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist.
These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.
|
|
These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care.
For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug.
Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.
|
|
Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case. |
|
These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care.
N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN. |
|
|
|
